Get the Daily Brief
Latest Biotech News
Gilead pays $2.2B for Ouro T‑cell engager – Galapagos to absorb assets
Gilead agreed to buy Ouro Medicines with roughly $1.675 billion upfront and up to $500 million in milestones to acquire OM336 (gamgertamig), a BCMAxCD3 T‑cell engager being tested in autoimmune...
Novartis snaps up Pikavation for $2B – bets on mutant‑selective PI3Kα
Novartis agreed to acquire Pikavation Therapeutics (a Synnovation subsidiary) for $2 billion upfront and up to $1 billion in milestones to secure SNV4818, a pan‑mutant‑selective PI3Kα inhibitor in...
Sanofi inks $1.2B deal for Kali trispecific – $180M up front
Sanofi struck a licensing deal with Kali Therapeutics for KT‑501, a CD19/BCMA/CD3 trispecific T‑cell engager dosed in a Phase Ia trial for rheumatoid arthritis. Kali receives $180 million in...
Apogee shows long‑acting eczema edge – investors bid shares higher
Apogee Therapeutics released Phase II maintenance data for its IL‑13 antibody zumilokibart (zumi, APG‑777) showing durable skin and itch improvement with dosing every three or six months. Company...
Pfizer, Valneva vaccine cuts Lyme by ~73%…statistical miss clouds regulatory path
Pfizer and Valneva reported Phase III Valor trial results showing roughly 70–73% efficacy against Lyme disease but missed the prespecified statistical boundary in the primary analysis because...
Rivia raises $15M to scale agentic AI for trials – eyes US expansion
Swiss startup Rivia closed a $15 million Series A led by Earlybird to advance an "agentic" AI platform that unifies and structures clinical trial data in real time. CEO Erik Scalfaro said proceeds...
Crossbow raises $77M Series B – T‑bolt engagers advance to clinic
Crossbow Therapeutics closed a $77 million Series B to fund its T‑Bolt platform and advance lead candidate CBX‑250, a T‑cell engager targeting peptide‑HLA complexes for myeloid malignancies,...
Immutrin nets $86M to advance amyloidosis antibody
Immutrin, a Cambridge, UK‑based biotech cofounded by Nobel laureate Gregory Winter, raised $86 million to advance an antibody program designed to deplete protein deposits in patients with...
Aardvark pauses ARD‑201 trials – entire pipeline on hold
Aardvark Therapeutics paused two Phase II studies of its oral weight‑loss asset ARD‑201 and put its broader pipeline on hold while it conducts a comprehensive data review and engages the FDA....
Metformin‑linked mechanism may delay HIV rebound – Gladstone multiomic study
Researchers at Gladstone Institutes published multiomic analyses in Immunity identifying cell‑intrinsic and extrinsic mechanisms tied to post‑treatment HIV control and reported that metformin...
Gilead pays $2.2B for T‑cell engager: Galapagos to absorb operations
Gilead struck a front‑loaded acquisition to secure OM336, a BCMAxCD3 T‑cell engager being developed for autoimmune blood disorders. The deal pays $1.675 billion up front with up to $500 million in...
Novartis to buy Pikavation for up to $3B: SNV4818 added to breast‑cancer suite
Novartis agreed to acquire Pikavation Therapeutics, a Synnovation subsidiary, in a deal that could total roughly $3 billion and centers on SNV4818, a pan‑mutant‑selective PI3Kα inhibitor now in...
Pfizer, Valneva to seek approval after mixed Lyme readout – 73% efficacy but statistical miss
Pfizer and Valneva said their Phase III Valor trial showed the Lyme disease vaccine candidate achieved about 73% efficacy but missed a prespecified statistical criterion, a result the partners...
Apogee touts long‑interval eczema wins – durable response with three‑ and six‑month dosing
Apogee reported Phase II maintenance data showing its IL‑13 antibody zumilokibart sustained clinical benefit with dosing every three or six months. The company disclosed durable EASI‑75 responses...
Sanofi pays $180M up front for Kali trispecific – deal could top $1.2B
Sanofi struck an exclusive worldwide license for Kali Therapeutics’ trispecific T‑cell engager KT‑501, paying $180 million in up‑front and near‑term payments with more than $1 billion in...
Crossbow nets $77M Series B – funds T‑Bolt T‑cell engagers for myeloid cancers
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and fund lead clinical work on CBX‑250, a T‑cell engager targeting relapsed or refractory myeloid malignancies....
Rivia raises $15M to scale agentic AI for clinical trials – targets Boston expansion
Swiss startup Rivia closed a $15 million Series A to develop an agentic AI platform that unifies trial data in real time and to expand in US biotech hubs, notably Boston. The company plans product...
Aardvark pauses obesity trials – entire pipeline on hold after safety review
Aardvark Therapeutics paused two Phase II trials of its oral weight‑loss candidate ARD‑201 while conducting a comprehensive data review; the decision follows a voluntary pause earlier in the...
IDT enters clinical IVD space – launches two Archer NGS library‑prep assays
Integrated DNA Technologies moved into the in vitro diagnostics market with two IVD next‑generation sequencing library‑preparation assays: Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx....
Oryon unveils neuron‑replacement Parkinson’s program; Ron Cohen joins as CEO
Oryon Cell Therapies emerged from stealth with Phase Ib/IIa data on an autologous neuron‑replacement therapy for Parkinson’s disease and announced new funding and leadership moves. The company...